Global Oral Antiepileptic Drug Market Growth 2024-2030

2024

Global Oral Antiepileptic Drug Market Growth 2024-2030

Name: Global Oral Antiepileptic Drug Market Growth 2024-2030
Brand: Bonafide Research
SKU: 95001329
Price: 3450 USD
Availability: InStock
Rating: 4 (9.15 reviews)

The global Oral Antiepileptic Drug market is projected to grow from US$ 11.1 billion in 2024 to US$ 15.1 billion in 2030.

Bonafide Trust
27-09-2024
Pages : 86
Figures : 85
Tables : 117
Region : Global
Category : Lifescience & Healthcare
Pharmaceutical

Schedule a Call

Buy Now Get Free sample

Request new version

Request for updated version of the report at the same price

Order Now

The global oral antiepileptic drug (AED) market is poised for substantial growth, driven by the increasing prevalence of epilepsy and other neurological disorders, along with the rising demand for more effective treatments for seizure management. Epilepsy is one of the most common neurological disorders, affecting millions of people worldwide, and it can significantly impact the quality of life. Oral antiepileptic drugs are the cornerstone of epilepsy treatment, as they help control and manage seizures by stabilizing electrical activity in the brain. The increasing number of epilepsy cases, particularly in emerging economies, along with advancements in pharmaceutical research and development, is fueling the demand for oral AEDs. The availability of a wide variety of oral AEDs that target different types of seizures and offer improved efficacy, safety, and tolerability has further bolstered market growth. The rising awareness about epilepsy, along with increased healthcare access in developing regions, is also contributing to the growing adoption of oral AEDs. Additionally, innovations in drug formulations, such as extended-release and combination therapies, have made treatment regimens more convenient and effective for patients. As a result, patients are increasingly opting for oral AEDs over alternative treatment options. Moreover, the market is witnessing an increase in the number of new drugs being introduced to treat epilepsy, driven by growing research in the field of epilepsy and neurological disorders. Governments and healthcare organizations are also actively investing in initiatives to raise awareness about epilepsy, which is expected to contribute to a more favorable market environment. The demand for oral AEDs is also being driven by the increasing aging population, as epilepsy is more prevalent among elderly individuals, and the need for more personalized and effective treatment options continues to rise. As a result, the global oral AED market is expanding rapidly, with a strong pipeline of drugs under development and increased market competition.

According to Publisher, the global Oral Antiepileptic Drug market size is projected to grow from US$ 11100 million in 2024 to US$ 15120 million in 2030; it is expected to grow at a CAGR of 5.3% from 2024 to 2030. The North American region holds the largest share of the global oral antiepileptic drug market, primarily due to the region’s advanced healthcare infrastructure, high healthcare expenditure, and a large patient population suffering from epilepsy. The United States is the leading market for oral AEDs, with a well-established healthcare system and a wide range of treatment options available for epilepsy patients. The presence of major pharmaceutical companies and strong government support for healthcare initiatives also plays a pivotal role in driving the growth of the oral AED market in North America. The increased prevalence of epilepsy, combined with the rising number of patients diagnosed with drug-resistant epilepsy, has created a substantial demand for oral antiepileptic drugs. Furthermore, innovations in drug development, including novel formulations and treatment regimens, have significantly expanded the range of available options for patients. The growing focus on personalized medicine in epilepsy treatment, where the selection of drugs is tailored to the specific needs of individual patients, is also contributing to the market growth in this region. Additionally, the region's strong reimbursement systems ensure better access to treatment for a larger population, further increasing market penetration. Europe is another key market for oral AEDs, with countries such as Germany, France, the United Kingdom, and Italy witnessing steady growth in the demand for these drugs. The increasing awareness about epilepsy and advancements in the treatment landscape are key drivers of the oral AED market in Europe. Furthermore, the rising prevalence of epilepsy in European countries, combined with government initiatives aimed at improving healthcare access, has resulted in a growing patient population seeking oral AED therapies. In the Asia-Pacific region, countries such as China, India, and Japan are expected to see significant growth in the oral AED market due to the increasing incidence of epilepsy, expanding healthcare infrastructure, and rising awareness of neurological disorders. As healthcare systems improve and access to treatments becomes more widespread, the demand for oral antiepileptic drugs in this region is expected to increase substantially. The Latin American and Middle Eastern markets are also witnessing growth, albeit at a slower pace, due to improving healthcare standards, government-funded initiatives, and rising awareness regarding epilepsy and its treatments.

What's Inside a Bonafide Research`s industry report?

A Bonafide Research industry report provides in-depth market analysis, trends, competitive insights, and strategic recommendations to help businesses make informed decisions.

Download Sample

The global oral antiepileptic drug market can be segmented by drug class, including sodium channel blockers, GABAergic drugs, glutamate antagonists, calcium channel blockers, and others. Sodium channel blockers are one of the most widely used drug classes for treating epilepsy, as they inhibit the transmission of electrical impulses in the brain, helping to prevent seizures. Drugs such as phenytoin, carbamazepine, and lamotrigine fall into this category and are commonly prescribed for both partial and generalized seizures. These drugs are particularly effective in managing focal and generalized tonic-clonic seizures, making them a first-line treatment option for many patients. GABAergic drugs, which enhance the effects of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter, are another significant segment in the oral AED market. Medications such as valproate and benzodiazepines belong to this class and are commonly used to treat various types of seizures, including generalized seizures, absence seizures, and myoclonic seizures. These drugs help balance the excitatory and inhibitory signals in the brain, thereby preventing seizure activity. Glutamate antagonists, which block the excitatory neurotransmitter glutamate, are emerging as an important class of drugs for the treatment of epilepsy. These drugs, such as perampanel, have shown efficacy in treating refractory epilepsy and are used in combination with other AEDs to improve treatment outcomes. Calcium channel blockers, including gabapentin and pregabalin, are also used for managing seizures, particularly in patients with neuropathic pain or epilepsy associated with other neurological conditions. In addition to these primary drug classes, the market also includes other emerging therapies, including cannabidiol (CBD) for treatment-resistant epilepsy, which has gained considerable attention in recent years. The continued development of new drugs and combination therapies in these categories is expected to further enhance the treatment options for epilepsy and drive growth in the oral AED market.

The application-based segmentation of the oral antiepileptic drug market includes the treatment of focal seizures, generalized seizures, and other seizure types. Focal seizures, also known as partial seizures, occur when abnormal electrical activity is confined to one area of the brain. These seizures are the most common type of epilepsy, and the treatment of focal seizures often involves medications such as carbamazepine, phenytoin, and lamotrigine. Oral AEDs used for focal seizures work by stabilizing the electrical activity in the affected area of the brain, preventing the spread of abnormal electrical impulses. Generalized seizures, which involve both sides of the brain and can lead to loss of consciousness, are another major application area for oral AEDs. Generalized tonic-clonic seizures, absence seizures, and myoclonic seizures are some examples of generalized seizures that are treated with AEDs such as valproate, levetiracetam, and topiramate. These drugs work by modulating neurotransmitter activity in the brain, inhibiting the spread of seizure activity, and helping patients maintain seizure control. In addition to focal and generalized seizures, oral AEDs are also used to manage other types of seizures, such as those associated with epilepsy syndromes like Lennox-Gastaut syndrome and Dravet syndrome. These syndromes are often characterized by severe, drug-resistant seizures that require a combination of oral AEDs for effective management. The increasing availability of newer oral AEDs with improved safety profiles and efficacy in treating various types of seizures is expected to contribute to the market's growth. Moreover, personalized treatment approaches, where AEDs are selected based on the individual patient’s seizure type and response to therapy, are also gaining traction, further boosting the demand for oral antiepileptic drugs. The continued advancements in epilepsy research and the development of new drugs will help address unmet needs in seizure management, ensuring the market's ongoing expansion.

Make this report your own

Have queries/questions regarding a report

Take advantage of intelligence tailored to your business objective

Sikandar Kesari

Research Analyst

Don’t pay for what you don’t need. Save 30%

Customise your report by selecting specific countries or regions

Specify Scope Now

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Oral Antiepileptic Drug Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Oral Antiepileptic Drug by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Oral Antiepileptic Drug by Country/Region, 2019, 2023 & 2030
2.2 Oral Antiepileptic Drug Segment by Type
2.2.1 First-generation
2.2.2 Second-generation
2.2.3 Third-generation
2.3 Oral Antiepileptic Drug Sales by Type
2.3.1 Global Oral Antiepileptic Drug Sales Market Share by Type (2019-2024)
2.3.2 Global Oral Antiepileptic Drug Revenue and Market Share by Type (2019-2024)
2.3.3 Global Oral Antiepileptic Drug Sale Price by Type (2019-2024)
2.4 Oral Antiepileptic Drug Segment by Application
2.4.1 Hospital Pharmacies
2.4.2 Retail Pharmacies
2.4.3 Online Pharmacies
2.4.4 Drug Stores
2.5 Oral Antiepileptic Drug Sales by Application
2.5.1 Global Oral Antiepileptic Drug Sale Market Share by Application (2019-2024)
2.5.2 Global Oral Antiepileptic Drug Revenue and Market Share by Application (2019-2024)
2.5.3 Global Oral Antiepileptic Drug Sale Price by Application (2019-2024)
3 Global by Company
3.1 Global Oral Antiepileptic Drug Breakdown Data by Company
3.1.1 Global Oral Antiepileptic Drug Annual Sales by Company (2019-2024)
3.1.2 Global Oral Antiepileptic Drug Sales Market Share by Company (2019-2024)
3.2 Global Oral Antiepileptic Drug Annual Revenue by Company (2019-2024)
3.2.1 Global Oral Antiepileptic Drug Revenue by Company (2019-2024)
3.2.2 Global Oral Antiepileptic Drug Revenue Market Share by Company (2019-2024)
3.3 Global Oral Antiepileptic Drug Sale Price by Company
3.4 Key Manufacturers Oral Antiepileptic Drug Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Oral Antiepileptic Drug Product Location Distribution
3.4.2 Players Oral Antiepileptic Drug Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 World Historic Review for Oral Antiepileptic Drug by Geographic Region
4.1 World Historic Oral Antiepileptic Drug Market Size by Geographic Region (2019-2024)
4.1.1 Global Oral Antiepileptic Drug Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Oral Antiepileptic Drug Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Oral Antiepileptic Drug Market Size by Country/Region (2019-2024)
4.2.1 Global Oral Antiepileptic Drug Annual Sales by Country/Region (2019-2024)
4.2.2 Global Oral Antiepileptic Drug Annual Revenue by Country/Region (2019-2024)
4.3 Americas Oral Antiepileptic Drug Sales Growth
4.4 APAC Oral Antiepileptic Drug Sales Growth
4.5 Europe Oral Antiepileptic Drug Sales Growth
4.6 Middle East & Africa Oral Antiepileptic Drug Sales Growth
5 Americas
5.1 Americas Oral Antiepileptic Drug Sales by Country
5.1.1 Americas Oral Antiepileptic Drug Sales by Country (2019-2024)
5.1.2 Americas Oral Antiepileptic Drug Revenue by Country (2019-2024)
5.2 Americas Oral Antiepileptic Drug Sales by Type (2019-2024)
5.3 Americas Oral Antiepileptic Drug Sales by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Oral Antiepileptic Drug Sales by Region
6.1.1 APAC Oral Antiepileptic Drug Sales by Region (2019-2024)
6.1.2 APAC Oral Antiepileptic Drug Revenue by Region (2019-2024)
6.2 APAC Oral Antiepileptic Drug Sales by Type (2019-2024)
6.3 APAC Oral Antiepileptic Drug Sales by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Oral Antiepileptic Drug by Country
7.1.1 Europe Oral Antiepileptic Drug Sales by Country (2019-2024)
7.1.2 Europe Oral Antiepileptic Drug Revenue by Country (2019-2024)
7.2 Europe Oral Antiepileptic Drug Sales by Type (2019-2024)
7.3 Europe Oral Antiepileptic Drug Sales by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Oral Antiepileptic Drug by Country
8.1.1 Middle East & Africa Oral Antiepileptic Drug Sales by Country (2019-2024)
8.1.2 Middle East & Africa Oral Antiepileptic Drug Revenue by Country (2019-2024)
8.2 Middle East & Africa Oral Antiepileptic Drug Sales by Type (2019-2024)
8.3 Middle East & Africa Oral Antiepileptic Drug Sales by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Oral Antiepileptic Drug
10.3 Manufacturing Process Analysis of Oral Antiepileptic Drug
10.4 Industry Chain Structure of Oral Antiepileptic Drug
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Oral Antiepileptic Drug Distributors
11.3 Oral Antiepileptic Drug Customer
12 World Forecast Review for Oral Antiepileptic Drug by Geographic Region
12.1 Global Oral Antiepileptic Drug Market Size Forecast by Region
12.1.1 Global Oral Antiepileptic Drug Forecast by Region (2025-2030)
12.1.2 Global Oral Antiepileptic Drug Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country (2025-2030)
12.3 APAC Forecast by Region (2025-2030)
12.4 Europe Forecast by Country (2025-2030)
12.5 Middle East & Africa Forecast by Country (2025-2030)
12.6 Global Oral Antiepileptic Drug Forecast by Type (2025-2030)
12.7 Global Oral Antiepileptic Drug Forecast by Application (2025-2030)
13 Key Players Analysis
13.1 Merck
13.1.1 Merck Company Information
13.1.2 Merck Oral Antiepileptic Drug Product Portfolios and Specifications
13.1.3 Merck Oral Antiepileptic Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Merck Main Business Overview
13.1.5 Merck Latest Developments
13.2 Eisai
13.2.1 Eisai Company Information
13.2.2 Eisai Oral Antiepileptic Drug Product Portfolios and Specifications
13.2.3 Eisai Oral Antiepileptic Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Eisai Main Business Overview
13.2.5 Eisai Latest Developments
13.3 AstraZeneca
13.3.1 AstraZeneca Company Information
13.3.2 AstraZeneca Oral Antiepileptic Drug Product Portfolios and Specifications
13.3.3 AstraZeneca Oral Antiepileptic Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 AstraZeneca Main Business Overview
13.3.5 AstraZeneca Latest Developments
13.4 Novartis
13.4.1 Novartis Company Information
13.4.2 Novartis Oral Antiepileptic Drug Product Portfolios and Specifications
13.4.3 Novartis Oral Antiepileptic Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Novartis Main Business Overview
13.4.5 Novartis Latest Developments
13.5 Abbott
13.5.1 Abbott Company Information
13.5.2 Abbott Oral Antiepileptic Drug Product Portfolios and Specifications
13.5.3 Abbott Oral Antiepileptic Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Abbott Main Business Overview
13.5.5 Abbott Latest Developments
13.6 Teva Pharmaceutical
13.6.1 Teva Pharmaceutical Company Information
13.6.2 Teva Pharmaceutical Oral Antiepileptic Drug Product Portfolios and Specifications
13.6.3 Teva Pharmaceutical Oral Antiepileptic Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Teva Pharmaceutical Main Business Overview
13.6.5 Teva Pharmaceutical Latest Developments
13.7 Pfizer
13.7.1 Pfizer Company Information
13.7.2 Pfizer Oral Antiepileptic Drug Product Portfolios and Specifications
13.7.3 Pfizer Oral Antiepileptic Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Pfizer Main Business Overview
13.7.5 Pfizer Latest Developments
13.8 GlaxoSmithKline
13.8.1 GlaxoSmithKline Company Information
13.8.2 GlaxoSmithKline Oral Antiepileptic Drug Product Portfolios and Specifications
13.8.3 GlaxoSmithKline Oral Antiepileptic Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 GlaxoSmithKline Main Business Overview
13.8.5 GlaxoSmithKline Latest Developments
13.9 Sanofi
13.9.1 Sanofi Company Information
13.9.2 Sanofi Oral Antiepileptic Drug Product Portfolios and Specifications
13.9.3 Sanofi Oral Antiepileptic Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Sanofi Main Business Overview
13.9.5 Sanofi Latest Developments
14 Research Findings and Conclusion

Table 1. Oral Antiepileptic Drug Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Oral Antiepileptic Drug Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of First-generation
Table 4. Major Players of Second-generation
Table 5. Major Players of Third-generation
Table 6. Global Oral Antiepileptic Drug Sales by Type (2019-2024) & (K Units)
Table 7. Global Oral Antiepileptic Drug Sales Market Share by Type (2019-2024)
Table 8. Global Oral Antiepileptic Drug Revenue by Type (2019-2024) & ($ million)
Table 9. Global Oral Antiepileptic Drug Revenue Market Share by Type (2019-2024)
Table 10. Global Oral Antiepileptic Drug Sale Price by Type (2019-2024) & (US$/Unit)
Table 11. Global Oral Antiepileptic Drug Sale by Application (2019-2024) & (K Units)
Table 12. Global Oral Antiepileptic Drug Sale Market Share by Application (2019-2024)
Table 13. Global Oral Antiepileptic Drug Revenue by Application (2019-2024) & ($ million)
Table 14. Global Oral Antiepileptic Drug Revenue Market Share by Application (2019-2024)
Table 15. Global Oral Antiepileptic Drug Sale Price by Application (2019-2024) & (US$/Unit)
Table 16. Global Oral Antiepileptic Drug Sales by Company (2019-2024) & (K Units)
Table 17. Global Oral Antiepileptic Drug Sales Market Share by Company (2019-2024)
Table 18. Global Oral Antiepileptic Drug Revenue by Company (2019-2024) & ($ millions)
Table 19. Global Oral Antiepileptic Drug Revenue Market Share by Company (2019-2024)
Table 20. Global Oral Antiepileptic Drug Sale Price by Company (2019-2024) & (US$/Unit)
Table 21. Key Manufacturers Oral Antiepileptic Drug Producing Area Distribution and Sales Area
Table 22. Players Oral Antiepileptic Drug Products Offered
Table 23. Oral Antiepileptic Drug Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 24. New Products and Potential Entrants
Table 25. Market M&A Activity & Strategy
Table 26. Global Oral Antiepileptic Drug Sales by Geographic Region (2019-2024) & (K Units)
Table 27. Global Oral Antiepileptic Drug Sales Market Share Geographic Region (2019-2024)
Table 28. Global Oral Antiepileptic Drug Revenue by Geographic Region (2019-2024) & ($ millions)
Table 29. Global Oral Antiepileptic Drug Revenue Market Share by Geographic Region (2019-2024)
Table 30. Global Oral Antiepileptic Drug Sales by Country/Region (2019-2024) & (K Units)
Table 31. Global Oral Antiepileptic Drug Sales Market Share by Country/Region (2019-2024)
Table 32. Global Oral Antiepileptic Drug Revenue by Country/Region (2019-2024) & ($ millions)
Table 33. Global Oral Antiepileptic Drug Revenue Market Share by Country/Region (2019-2024)
Table 34. Americas Oral Antiepileptic Drug Sales by Country (2019-2024) & (K Units)
Table 35. Americas Oral Antiepileptic Drug Sales Market Share by Country (2019-2024)
Table 36. Americas Oral Antiepileptic Drug Revenue by Country (2019-2024) & ($ millions)
Table 37. Americas Oral Antiepileptic Drug Sales by Type (2019-2024) & (K Units)
Table 38. Americas Oral Antiepileptic Drug Sales by Application (2019-2024) & (K Units)
Table 39. APAC Oral Antiepileptic Drug Sales by Region (2019-2024) & (K Units)
Table 40. APAC Oral Antiepileptic Drug Sales Market Share by Region (2019-2024)
Table 41. APAC Oral Antiepileptic Drug Revenue by Region (2019-2024) & ($ millions)
Table 42. APAC Oral Antiepileptic Drug Sales by Type (2019-2024) & (K Units)
Table 43. APAC Oral Antiepileptic Drug Sales by Application (2019-2024) & (K Units)
Table 44. Europe Oral Antiepileptic Drug Sales by Country (2019-2024) & (K Units)
Table 45. Europe Oral Antiepileptic Drug Revenue by Country (2019-2024) & ($ millions)
Table 46. Europe Oral Antiepileptic Drug Sales by Type (2019-2024) & (K Units)
Table 47. Europe Oral Antiepileptic Drug Sales by Application (2019-2024) & (K Units)
Table 48. Middle East & Africa Oral Antiepileptic Drug Sales by Country (2019-2024) & (K Units)
Table 49. Middle East & Africa Oral Antiepileptic Drug Revenue Market Share by Country (2019-2024)
Table 50. Middle East & Africa Oral Antiepileptic Drug Sales by Type (2019-2024) & (K Units)
Table 51. Middle East & Africa Oral Antiepileptic Drug Sales by Application (2019-2024) & (K Units)
Table 52. Key Market Drivers & Growth Opportunities of Oral Antiepileptic Drug
Table 53. Key Market Challenges & Risks of Oral Antiepileptic Drug
Table 54. Key Industry Trends of Oral Antiepileptic Drug
Table 55. Oral Antiepileptic Drug Raw Material
Table 56. Key Suppliers of Raw Materials
Table 57. Oral Antiepileptic Drug Distributors List
Table 58. Oral Antiepileptic Drug Customer List
Table 59. Global Oral Antiepileptic Drug Sales Forecast by Region (2025-2030) & (K Units)
Table 60. Global Oral Antiepileptic Drug Revenue Forecast by Region (2025-2030) & ($ millions)
Table 61. Americas Oral Antiepileptic Drug Sales Forecast by Country (2025-2030) & (K Units)
Table 62. Americas Oral Antiepileptic Drug Annual Revenue Forecast by Country (2025-2030) & ($ millions)
Table 63. APAC Oral Antiepileptic Drug Sales Forecast by Region (2025-2030) & (K Units)
Table 64. APAC Oral Antiepileptic Drug Annual Revenue Forecast by Region (2025-2030) & ($ millions)
Table 65. Europe Oral Antiepileptic Drug Sales Forecast by Country (2025-2030) & (K Units)
Table 66. Europe Oral Antiepileptic Drug Revenue Forecast by Country (2025-2030) & ($ millions)
Table 67. Middle East & Africa Oral Antiepileptic Drug Sales Forecast by Country (2025-2030) & (K Units)
Table 68. Middle East & Africa Oral Antiepileptic Drug Revenue Forecast by Country (2025-2030) & ($ millions)
Table 69. Global Oral Antiepileptic Drug Sales Forecast by Type (2025-2030) & (K Units)
Table 70. Global Oral Antiepileptic Drug Revenue Forecast by Type (2025-2030) & ($ millions)
Table 71. Global Oral Antiepileptic Drug Sales Forecast by Application (2025-2030) & (K Units)
Table 72. Global Oral Antiepileptic Drug Revenue Forecast by Application (2025-2030) & ($ millions)
Table 73. Merck Basic Information, Oral Antiepileptic Drug Manufacturing Base, Sales Area and Its Competitors
Table 74. Merck Oral Antiepileptic Drug Product Portfolios and Specifications
Table 75. Merck Oral Antiepileptic Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 76. Merck Main Business
Table 77. Merck Latest Developments
Table 78. Eisai Basic Information, Oral Antiepileptic Drug Manufacturing Base, Sales Area and Its Competitors
Table 79. Eisai Oral Antiepileptic Drug Product Portfolios and Specifications
Table 80. Eisai Oral Antiepileptic Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 81. Eisai Main Business
Table 82. Eisai Latest Developments
Table 83. AstraZeneca Basic Information, Oral Antiepileptic Drug Manufacturing Base, Sales Area and Its Competitors
Table 84. AstraZeneca Oral Antiepileptic Drug Product Portfolios and Specifications
Table 85. AstraZeneca Oral Antiepileptic Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 86. AstraZeneca Main Business
Table 87. AstraZeneca Latest Developments
Table 88. Novartis Basic Information, Oral Antiepileptic Drug Manufacturing Base, Sales Area and Its Competitors
Table 89. Novartis Oral Antiepileptic Drug Product Portfolios and Specifications
Table 90. Novartis Oral Antiepileptic Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 91. Novartis Main Business
Table 92. Novartis Latest Developments
Table 93. Abbott Basic Information, Oral Antiepileptic Drug Manufacturing Base, Sales Area and Its Competitors
Table 94. Abbott Oral Antiepileptic Drug Product Portfolios and Specifications
Table 95. Abbott Oral Antiepileptic Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 96. Abbott Main Business
Table 97. Abbott Latest Developments
Table 98. Teva Pharmaceutical Basic Information, Oral Antiepileptic Drug Manufacturing Base, Sales Area and Its Competitors
Table 99. Teva Pharmaceutical Oral Antiepileptic Drug Product Portfolios and Specifications
Table 100. Teva Pharmaceutical Oral Antiepileptic Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 101. Teva Pharmaceutical Main Business
Table 102. Teva Pharmaceutical Latest Developments
Table 103. Pfizer Basic Information, Oral Antiepileptic Drug Manufacturing Base, Sales Area and Its Competitors
Table 104. Pfizer Oral Antiepileptic Drug Product Portfolios and Specifications
Table 105. Pfizer Oral Antiepileptic Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 106. Pfizer Main Business
Table 107. Pfizer Latest Developments
Table 108. GlaxoSmithKline Basic Information, Oral Antiepileptic Drug Manufacturing Base, Sales Area and Its Competitors
Table 109. GlaxoSmithKline Oral Antiepileptic Drug Product Portfolios and Specifications
Table 110. GlaxoSmithKline Oral Antiepileptic Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 111. GlaxoSmithKline Main Business
Table 112. GlaxoSmithKline Latest Developments
Table 113. Sanofi Basic Information, Oral Antiepileptic Drug Manufacturing Base, Sales Area and Its Competitors
Table 114. Sanofi Oral Antiepileptic Drug Product Portfolios and Specifications
Table 115. Sanofi Oral Antiepileptic Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 116. Sanofi Main Business
Table 117. Sanofi Latest Developments

List of

Figure 1. Picture of Oral Antiepileptic Drug
Figure 2. Oral Antiepileptic Drug Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Oral Antiepileptic Drug Sales Growth Rate 2019-2030 (K Units)
Figure 7. Global Oral Antiepileptic Drug Revenue Growth Rate 2019-2030 ($ millions)
Figure 8. Oral Antiepileptic Drug Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 9. Oral Antiepileptic Drug Sales Market Share by Country/Region (2023)
Figure 10. Oral Antiepileptic Drug Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 11. Product Picture of First-generation
Figure 12. Product Picture of Second-generation
Figure 13. Product Picture of Third-generation
Figure 14. Global Oral Antiepileptic Drug Sales Market Share by Type in 2023
Figure 15. Global Oral Antiepileptic Drug Revenue Market Share by Type (2019-2024)
Figure 16. Oral Antiepileptic Drug Consumed in Hospital Pharmacies
Figure 17. Global Oral Antiepileptic Drug Market: Hospital Pharmacies (2019-2024) & (K Units)
Figure 18. Oral Antiepileptic Drug Consumed in Retail Pharmacies
Figure 19. Global Oral Antiepileptic Drug Market: Retail Pharmacies (2019-2024) & (K Units)
Figure 20. Oral Antiepileptic Drug Consumed in Online Pharmacies
Figure 21. Global Oral Antiepileptic Drug Market: Online Pharmacies (2019-2024) & (K Units)
Figure 22. Oral Antiepileptic Drug Consumed in Drug Stores
Figure 23. Global Oral Antiepileptic Drug Market: Drug Stores (2019-2024) & (K Units)
Figure 24. Global Oral Antiepileptic Drug Sale Market Share by Application (2023)
Figure 25. Global Oral Antiepileptic Drug Revenue Market Share by Application in 2023
Figure 26. Oral Antiepileptic Drug Sales by Company in 2023 (K Units)
Figure 27. Global Oral Antiepileptic Drug Sales Market Share by Company in 2023
Figure 28. Oral Antiepileptic Drug Revenue by Company in 2023 ($ millions)
Figure 29. Global Oral Antiepileptic Drug Revenue Market Share by Company in 2023
Figure 30. Global Oral Antiepileptic Drug Sales Market Share by Geographic Region (2019-2024)
Figure 31. Global Oral Antiepileptic Drug Revenue Market Share by Geographic Region in 2023
Figure 32. Americas Oral Antiepileptic Drug Sales 2019-2024 (K Units)
Figure 33. Americas Oral Antiepileptic Drug Revenue 2019-2024 ($ millions)
Figure 34. APAC Oral Antiepileptic Drug Sales 2019-2024 (K Units)
Figure 35. APAC Oral Antiepileptic Drug Revenue 2019-2024 ($ millions)
Figure 36. Europe Oral Antiepileptic Drug Sales 2019-2024 (K Units)
Figure 37. Europe Oral Antiepileptic Drug Revenue 2019-2024 ($ millions)
Figure 38. Middle East & Africa Oral Antiepileptic Drug Sales 2019-2024 (K Units)
Figure 39. Middle East & Africa Oral Antiepileptic Drug Revenue 2019-2024 ($ millions)
Figure 40. Americas Oral Antiepileptic Drug Sales Market Share by Country in 2023
Figure 41. Americas Oral Antiepileptic Drug Revenue Market Share by Country (2019-2024)
Figure 42. Americas Oral Antiepileptic Drug Sales Market Share by Type (2019-2024)
Figure 43. Americas Oral Antiepileptic Drug Sales Market Share by Application (2019-2024)
Figure 44. United States Oral Antiepileptic Drug Revenue Growth 2019-2024 ($ millions)
Figure 45. Canada Oral Antiepileptic Drug Revenue Growth 2019-2024 ($ millions)
Figure 46. Mexico Oral Antiepileptic Drug Revenue Growth 2019-2024 ($ millions)
Figure 47. Brazil Oral Antiepileptic Drug Revenue Growth 2019-2024 ($ millions)
Figure 48. APAC Oral Antiepileptic Drug Sales Market Share by Region in 2023
Figure 49. APAC Oral Antiepileptic Drug Revenue Market Share by Region (2019-2024)
Figure 50. APAC Oral Antiepileptic Drug Sales Market Share by Type (2019-2024)
Figure 51. APAC Oral Antiepileptic Drug Sales Market Share by Application (2019-2024)
Figure 52. China Oral Antiepileptic Drug Revenue Growth 2019-2024 ($ millions)
Figure 53. Japan Oral Antiepileptic Drug Revenue Growth 2019-2024 ($ millions)
Figure 54. South Korea Oral Antiepileptic Drug Revenue Growth 2019-2024 ($ millions)
Figure 55. Southeast Asia Oral Antiepileptic Drug Revenue Growth 2019-2024 ($ millions)
Figure 56. India Oral Antiepileptic Drug Revenue Growth 2019-2024 ($ millions)
Figure 57. Australia Oral Antiepileptic Drug Revenue Growth 2019-2024 ($ millions)
Figure 58. China Taiwan Oral Antiepileptic Drug Revenue Growth 2019-2024 ($ millions)
Figure 59. Europe Oral Antiepileptic Drug Sales Market Share by Country in 2023
Figure 60. Europe Oral Antiepileptic Drug Revenue Market Share by Country (2019-2024)
Figure 61. Europe Oral Antiepileptic Drug Sales Market Share by Type (2019-2024)
Figure 62. Europe Oral Antiepileptic Drug Sales Market Share by Application (2019-2024)
Figure 63. Germany Oral Antiepileptic Drug Revenue Growth 2019-2024 ($ millions)
Figure 64. France Oral Antiepileptic Drug Revenue Growth 2019-2024 ($ millions)
Figure 65. UK Oral Antiepileptic Drug Revenue Growth 2019-2024 ($ millions)
Figure 66. Italy Oral Antiepileptic Drug Revenue Growth 2019-2024 ($ millions)
Figure 67. Russia Oral Antiepileptic Drug Revenue Growth 2019-2024 ($ millions)
Figure 68. Middle East & Africa Oral Antiepileptic Drug Sales Market Share by Country (2019-2024)
Figure 69. Middle East & Africa Oral Antiepileptic Drug Sales Market Share by Type (2019-2024)
Figure 70. Middle East & Africa Oral Antiepileptic Drug Sales Market Share by Application (2019-2024)
Figure 71. Egypt Oral Antiepileptic Drug Revenue Growth 2019-2024 ($ millions)
Figure 72. South Africa Oral Antiepileptic Drug Revenue Growth 2019-2024 ($ millions)
Figure 73. Israel Oral Antiepileptic Drug Revenue Growth 2019-2024 ($ millions)
Figure 74. Turkey Oral Antiepileptic Drug Revenue Growth 2019-2024 ($ millions)
Figure 75. GCC Countries Oral Antiepileptic Drug Revenue Growth 2019-2024 ($ millions)
Figure 76. Manufacturing Cost Structure Analysis of Oral Antiepileptic Drug in 2023
Figure 77. Manufacturing Process Analysis of Oral Antiepileptic Drug
Figure 78. Industry Chain Structure of Oral Antiepileptic Drug
Figure 79. Channels of Distribution
Figure 80. Global Oral Antiepileptic Drug Sales Market Forecast by Region (2025-2030)
Figure 81. Global Oral Antiepileptic Drug Revenue Market Share Forecast by Region (2025-2030)
Figure 82. Global Oral Antiepileptic Drug Sales Market Share Forecast by Type (2025-2030)
Figure 83. Global Oral Antiepileptic Drug Revenue Market Share Forecast by Type (2025-2030)
Figure 84. Global Oral Antiepileptic Drug Sales Market Share Forecast by Application (2025-2030)
Figure 85. Global Oral Antiepileptic Drug Revenue Market Share Forecast by Application (2025-2030)

Related Reports

One individual can access, store, display, or archive the report in Excel format but cannot print, copy, or share it. Use is confidential and internal only. License information

One individual can access, store, display, or archive the report in PDF format but cannot print, copy, or share it. Use is confidential and internal only. License information

Up to 10 employees in one region can store, display, duplicate, and archive the report for internal use. Use is confidential and printable. License information

All employees globally can access, print, copy, and cite data externally (with attribution to Bonafide Research). License information

Safe and Secure SSL Encrypted